MULTIMALVAX
A Multi-Stage Malaria Vaccine
| Coordinatore | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.multimalvax.eu/home |
| Totale costo | 8˙063˙004 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | coordinator | 3˙500˙000.00 |
| 2 |
REITHERA SRL
Organization address
address: VIA GAETANO SALVATORE 486 contact info |
IT (Napoli) | participant | 1˙300˙000.00 |
| 3 |
EUROPEAN VACCINE INITIATIVE - EEIG
Organization address
address: IM NEUERHEIMER FELD 307 contact info |
DE (Heidelberg) | participant | 700˙000.00 |
| 4 |
UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
Organization address
address: Place Jussieu 4 contact info |
FR (PARIS) | participant | 300˙000.00 |
| 5 |
GLAXOSMITHKLINE VACCINES SRL
Organization address
address: Via Fiorentina 1 contact info |
IT (SIENA) | participant | 200˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas. Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life-cycle allow testing of a multi-stage multi-component vaccine for the first time, with strong chances of success. These advances are i) the availability of a new vectored prime-boost vaccination regime based on the Okairos chimpanzee adenovirus technology that has been found to induce exceptionally potent CD8 T cell responses and high titre antibodies against multiple malaria antigens; ii) the development of an improved version of the leading partially protective RTS,S sporozoite vaccine candidate, termed R21, that lacks the excess of HBsAg in RTS,S; iii) the identification, using a vector technology screen, of the blood-stage antigen RH5 as the first antigen to induce potent strain-transcending neutralisation of blood-stage parasites in in vitro growth inhibition assays; and iv) the demonstration that vector-induced antibodies against two mosquito-stage antigens can induce 100% transmission blocking against field isolates of P. falciparum in Africa. We will undertake four phase I / II clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components individually, and then together, using state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product.'
Introduzione (Teaser)
Malaria continues to affect millions of people worldwide. Vaccine development has been one of the main struggles of health research globally.